The newly published PICaSSO characterises subtle mucosal and vascular changes and defines mucosal healing, which has become an important goal in UC treatment. In a real-life study, PICaSSO was validated and its ability to predict relapse assessed. A total of 278 patients with UC were prospectively recruited from 11 international centres. Participating endoscopists received training on PICaSSO. For histological assessment, Robarts (RHI) and Nancy histological indexes (NI) were used.
The diagnostic performance of PICaSSO in predicting histological healing is shown in the Table. A PICaSSO of ≤3 for mucosal and vascular architecture resulted in a fair to good prediction of healing, both by RHI and NHI. A total PICaSSO of ≤8 and an Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score of ≤1 also predicted remission after 1 year. A Kaplan–Meier curve showed a favourable chance of survival without relapse with a PICaSSO of ≤8.
Table. Sensitivity, specificity, and accuracy in predicting histological healing [1]
RHI, Robarts histological indexes; NI, Nancy histological indexes; UCEIS, Ulcerative Colitis Endoscopic Index of Severity
- Iacucci M, et al. ECCO-IBD 2020, OP26.
Posted on
Previous Article
« Re-inducing inflammation in organoids from UC patients Next Article
Resolution of mucosal inflammation has dramatic effect »
« Re-inducing inflammation in organoids from UC patients Next Article
Resolution of mucosal inflammation has dramatic effect »
Table of Contents: ECCO 2020
Featured articles
Gut Microbiome as Treatment Target
Response to faecal microbiota transplantation in UC
Bioactives produced by gut bacteria to modulate immune response
Big Data Analysis
Multi-omics help describe CD phenotypes
The positive impact of genetic data on drug development
Experimental Therapies: Study Results
AMT-101: an oral human IL-10 fusion protein
Phase 2 results of first-in-class TL1A inhibitor
Open-label extension study of risankizumab: final results
Clinical remission after dose escalation of upadacitinib
Short- and Long-Term Treatment Results
Infliximab discontinuation increases relapse risk
Tofacitinib ‘real-world’ effectiveness in active UC
Subcutaneous ustekinumab as maintenance therapy in UC
Subcutaneous vedolizumab maintenance therapy in CD
Vedolizumab treatment persistence and safety
Specific Therapeutic Strategies
Impact of strategies on intestinal resection rate
Early ileocaecal resection in CD patients failing conventional treatment
Biologics before surgery in IBD do not elevate infection risk
Top-down infliximab superior to step-up in children with CD
High versus standard adalimumab in active UC
Head-to-Head Comparison of Treatments
Vedolizumab and anti-TNF therapies: a real-world comparison
Cancer Risk
Increased risk of small bowel cancer in IBD
Increased incidence of colorectal cancer and death in CD
Risk of rectal, anal cancer increased in perianal CD
Glyco-fingerprint as risk factor of UC-associated cancer
Miscellaneous Topics
Resolution of mucosal inflammation has dramatic effect
PICaSSO validated in real-life study
Re-inducing inflammation in organoids from UC patients
Role of immune cells in intestinal fibrosis
Association between meat consumption and IBD risk
CD exclusion diet corrects dysbiosis
Related Articles
April 14, 2020
Multi-omics help describe CD phenotypes
April 14, 2020
Impact of strategies on intestinal resection rate
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy
HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com